# Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

> **NCT03076203** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 14 (actual)

## Conditions studied

- Prostate Carcinoma Metastatic to the Bone
- Stage IV Prostate Adenocarcinoma
- Hormone-refractory Prostate Cancer

## Interventions

- **DRUG:** Niraparib
- **RADIATION:** Radium Ra 223 Dichloride

## Key facts

- **NCT ID:** NCT03076203
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-22
- **Primary completion:** 2020-01-13
- **Final completion:** 2022-11-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03076203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03076203, "Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03076203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*